Where will the future of orphan drugs and gene therapies lead to? – SKC in discourse at Harvard and Boston
About the author
Prof. Matthias P. Schönermark, M.D., Ph.D.
Founder and Managing Director
Founder and Managing Director
Fon: +49 511 64 68 14 – 0
Fax: +49 511 64 68 14 18
Fax: +49 511 64 68 14 18
SKC kicked-off the journey by holding two seminars at the Harvard Faculty Club with a key focus on strategical market access for orphan drugs and gene therapies in Europe. Barriers of and possible solutions for the European and German market access for these innovative medications were debated. The discussions were led by Prof. Matthias P. Schönermark, M.D., Ph. D., managing director of SKC and senior consultant Tim Kirchmann.
The implications of rare diseases were brilliantly illustrated at the congress “Orphan Drugs and Rare Diseases” on the following days: the sum of patients suffering from a rare disease is estimated to be much higher than the amount of cancer- and HIV-patients together. Different stakeholders (like patient organizations, developers and hospitals) held impressive speeches, reporting about their contribution to rare diseases. Prof. Schönermark pointed out strategies and reimbursement paths for orphan drugs in Europe, both during his keynote and his panel discussion. “The lectures and conversations clearly showed me that it is a such a privilege to work in this field and to develop a market, which can improve the situation of the European patients.”, concluded Prof. Schönermark about the 8th congress of this kind held on the U.S. east coast.
As the leading strategy consulting in the German health care sector, SKC consulting has been supporting pharmaceutical entrepreneurs at their market access for orphan drugs since many years and is knowledge holder in the field of gene therapies.
Get more insights by requesting our free-of-charge white papers Successful market access for gene therapies and Orphan Drugs in Germany – Lessons learned from AMNOG.
BY Prof. Matthias P. Schönermark, M.D., Ph.D., managing director and Karolin Priese, MBA